Press Releases

Company News
Summary ToggleAcura Pharmaceuticals Announces First Quarter 2019 Financial Results
Oct 01, 2019
PALATINE, Ill. , Oct. 01, 2019 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. , a specialty pharmaceutical company engaged in the research, development and commercialization of technologies and product candidates intended to mitigate the risk of outcomes associated with product misuse announced,

Read more

Summary ToggleAcura Pharmaceuticals Announces Fourth Quarter 2018 and Full Year 2018 Financial Results
Sep 16, 2019
PALATINE, Ill. , Sept. 16, 2019 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. , a specialty pharmaceutical company engaged in the research, development and commercialization of technologies and product candidates intended to mitigate the risk of outcomes associated with product misuse announced

Read more

Summary ToggleAcura Pharmaceuticals Engages Catalent Pharma Solutions to Advance Development of LTX-03
Sep 09, 2019
PALATINE, Ill. , Sept. 09, 2019 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTC Pink: ACUR), today announced that it has engaged Catalent Pharma Solutions, LLC (“Catalent”) to initiate manufacturing scale-up of LTX-03 (Hydrocodone Bitartrate and Acetaminophen) Tablets to ultimately be used in

Read more

Summary ToggleAcura Pharmaceuticals Licenses LIMITx™ LTX-03
Jul 02, 2019
Agreement Provides For Completion of Development and Commercialization Transaction Valued at up to $21.3 Million , not including Royalties PALATINE, Ill. , July 02, 2019 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTC Pink: ACUR) today announced a License, Development and Commercialization

Read more

Summary ToggleAcura Pharmaceuticals Announces Third Quarter 2018 Financial Results
Nov 27, 2018
PALATINE, Ill. , Nov. 27, 2018 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial results for the three and nine months ended September 30, 2018 .

Read more

Summary ToggleAcura Pharmaceuticals, Inc. Restructures Debt Obligations
Oct 09, 2018
PALATINE, Ill. , Oct. 09, 2018 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR) , a specialty pharmaceutical company focused on innovating abuse deterrent drugs , today announced that on October 5, 2018 we restructured our debt obligations by (a) receiving an additional $1.8 million

Read more

Summary ToggleAcura Pharmaceuticals Announces Second Quarter 2018 Financial Results
Aug 14, 2018

PALATINE, Ill. , Aug. 14, 2018 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial results for the three and six months ended June 30, 2018 . The Company reported a net loss of $2.8 million or

Read more

Summary ToggleAcura Pharmaceuticals Announces First Quarter 2018 Financial Results
Jun 29, 2018

PALATINE, Ill. , June 29, 2018 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTC PINK:ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial results for the three months ended March 31, 2018 . The Company reported for the first quarter 2018 a net

Read more

Summary ToggleAcura Pharmaceuticals Announces Fourth Quarter 2017 and Full Year 2017 Financial Results
Jun 07, 2018

PALATINE, Ill. , June 07, 2018 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTC PINK:ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial results for the three and twelve months ended December 31, 2017 .

Read more

Summary ToggleAcura Pharmaceuticals Announces Successful Results from Study AP-LTX-301
Jan 08, 2018
*** LIMITx™ Product LTX-03 Advancing to IND ***

Read more

Summary ToggleAcura Pharmaceuticals Announces Third Quarter 2017 Financial Results
Nov 13, 2017
PALATINE, Ill. , Nov. 13, 2017 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB:ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial results for the three and nine months ended September 30, 2017 .

Read more

Summary ToggleAcura Pharmaceuticals Advances LTX-03 and its LIMITx™ Technology
Oct 09, 2017
PALATINE, Ill. , Oct. 09, 2017 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB:ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs , today announced that topline results from clinical study AP-LTX-300 (Study 300) for its LIMITx™ oral abuse deterrent drug LTX-03

Read more

Summary ToggleAcura Pharmaceuticals Presenting New LIMITx™ Clinical Data at the 19th Annual Rodman & Renshaw Conference
Sep 11, 2017
PALATINE, Ill. , Sept. 11, 2017 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB:ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs , today announced the results from the previously undisclosed exploratory arm of its second LIMITx™ clinical study, study

Read more

Summary ToggleAcura Pharmaceuticals to Present at the 19th Annual RODMAN & RENSHAW Conference
Aug 31, 2017
PALATINE, Ill. , Aug. 31, 2017 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB:ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, today announced that Bob Jones , President and Chief Executive Officer, will present at the 19 th Annual Rodman & Renshaw Global

Read more

Summary ToggleAcura Pharmaceuticals Announces Second Quarter 2017 Financial Results
Aug 14, 2017
PALATINE, Ill. , Aug. 14, 2017 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB:ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial results for the three and six months ended June 30, 2017 . The Company reported a net loss of $2.15 million or

Read more

Summary ToggleAcura Pharmaceuticals to Host Second Quarter 2017 Financial Results Conference Call on August 15, 2017
Aug 03, 2017
PALATINE, Ill. , Aug. 03, 2017 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB:ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs , today announced that the Company plans to report financial results for the second quarter 2017 following the close of financial markets

Read more

Summary ToggleAcura Pharmaceuticals Raises $4.0 Million in a Private Placement
Jul 24, 2017

*** Provides Funding to Advance Development of Products Utilizing LIMITx™ Technology ***

Read more

Summary ToggleAcura Pharmaceuticals Advances LTX-04 and its LIMITx™ Technology
Jun 28, 2017

*** Peak blood levels of abused LIMITx doses can be reduced up to 65% ***

Read more

Displaying 19 - 36 of 160 results